SG11202105506UA - Combination therapies for high and very high risk mds - Google Patents
Combination therapies for high and very high risk mdsInfo
- Publication number
- SG11202105506UA SG11202105506UA SG11202105506UA SG11202105506UA SG11202105506UA SG 11202105506U A SG11202105506U A SG 11202105506UA SG 11202105506U A SG11202105506U A SG 11202105506UA SG 11202105506U A SG11202105506U A SG 11202105506UA SG 11202105506U A SG11202105506U A SG 11202105506UA
- Authority
- SG
- Singapore
- Prior art keywords
- combination therapies
- risk mds
- high risk
- mds
- therapies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773490P | 2018-11-30 | 2018-11-30 | |
| PCT/US2019/063360 WO2020112848A1 (en) | 2018-11-30 | 2019-11-26 | Combination therapies for high and very high risk mds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105506UA true SG11202105506UA (en) | 2021-06-29 |
Family
ID=70854408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105506UA SG11202105506UA (en) | 2018-11-30 | 2019-11-26 | Combination therapies for high and very high risk mds |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220016082A1 (en) |
| EP (1) | EP3886865A4 (en) |
| JP (1) | JP2022511746A (en) |
| KR (1) | KR20210097157A (en) |
| CN (1) | CN113412115A (en) |
| AU (1) | AU2019389004A1 (en) |
| BR (1) | BR112021010101A2 (en) |
| CA (1) | CA3121188A1 (en) |
| EA (1) | EA202191503A1 (en) |
| IL (1) | IL283464A (en) |
| MA (1) | MA54322A (en) |
| MX (1) | MX2021006127A (en) |
| SG (1) | SG11202105506UA (en) |
| WO (1) | WO2020112848A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8404716B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| RS60122B1 (en) * | 2012-10-30 | 2020-05-29 | Mei Pharma Inc | Combination therapies to treat chemoresistant cancers |
| US10052346B2 (en) * | 2015-02-17 | 2018-08-21 | Cantex Pharmaceuticals, Inc. | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids |
-
2019
- 2019-11-26 KR KR1020217019884A patent/KR20210097157A/en unknown
- 2019-11-26 SG SG11202105506UA patent/SG11202105506UA/en unknown
- 2019-11-26 WO PCT/US2019/063360 patent/WO2020112848A1/en unknown
- 2019-11-26 AU AU2019389004A patent/AU2019389004A1/en not_active Abandoned
- 2019-11-26 EA EA202191503A patent/EA202191503A1/en unknown
- 2019-11-26 EP EP19891614.0A patent/EP3886865A4/en not_active Withdrawn
- 2019-11-26 BR BR112021010101-2A patent/BR112021010101A2/en not_active Application Discontinuation
- 2019-11-26 MA MA054322A patent/MA54322A/en unknown
- 2019-11-26 US US17/294,513 patent/US20220016082A1/en not_active Abandoned
- 2019-11-26 MX MX2021006127A patent/MX2021006127A/en unknown
- 2019-11-26 CN CN201980090984.8A patent/CN113412115A/en active Pending
- 2019-11-26 CA CA3121188A patent/CA3121188A1/en active Pending
- 2019-11-26 JP JP2021528453A patent/JP2022511746A/en active Pending
-
2021
- 2021-05-26 IL IL283464A patent/IL283464A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019389004A1 (en) | 2021-07-15 |
| US20220016082A1 (en) | 2022-01-20 |
| CN113412115A (en) | 2021-09-17 |
| CA3121188A1 (en) | 2020-06-04 |
| MX2021006127A (en) | 2021-06-23 |
| MA54322A (en) | 2021-10-06 |
| BR112021010101A2 (en) | 2021-08-24 |
| EP3886865A4 (en) | 2022-11-23 |
| JP2022511746A (en) | 2022-02-01 |
| KR20210097157A (en) | 2021-08-06 |
| EA202191503A1 (en) | 2021-11-15 |
| IL283464A (en) | 2021-07-29 |
| WO2020112848A1 (en) | 2020-06-04 |
| EP3886865A1 (en) | 2021-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202102016B (en) | Combination therapies | |
| IL271011A (en) | Triple combination antibody therapies | |
| IL274407A (en) | Combination therapies | |
| EP3612181A4 (en) | Combination therapies with ehmt2 inhibitors | |
| IL273510A (en) | Combination therapies and uses thereof | |
| HK1254953A1 (en) | Anti-vista antibodies and fragments | |
| IL291659A (en) | Combination therapies | |
| IL270511A (en) | Combination therapies using niraparib and pembrolizumab for treating cancer | |
| EP3849535A4 (en) | Combination therapies | |
| EP3849536A4 (en) | Combination therapies | |
| EP3548064A4 (en) | Anti-hrs antibodies and combination therapies for treating cancers | |
| SG11202002862RA (en) | Combination therapies for treating cancer | |
| ZA202102015B (en) | Combination therapies | |
| EP3359255A4 (en) | Combination therapies for treating cancer | |
| EP3849534A4 (en) | Combination therapies | |
| ZA202102727B (en) | Immunoablative therapies | |
| EP3860609A4 (en) | Combination therapies | |
| HK1243598A1 (en) | Combination therapies | |
| HK1245120A1 (en) | Novel therapies for cancer | |
| EP3849537A4 (en) | Combination therapies | |
| EP3876988A4 (en) | Cdcp1-targeted therapies | |
| IL281132A (en) | Combination therapies comprising pd-1-based chimeric proteins | |
| EP3601363A4 (en) | Alt-803 in combination with anti-cd38 antibody for cancer therapies | |
| GB2580963B (en) | Cancer therapies | |
| EP3849310A4 (en) | Combination cancer therapies |